Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 5024Carcinoma, Renal Cell 1577Urinary Bladder Neoplasms 1279Kidney Neoplasms 724Breast Neoplasms 643Neoplasms 630Carcinoma, Transitional Cell 490Carcinoma, Non-Small-Cell Lung 469Neoplasm Metastasis 468Melanoma 422Ovarian Neoplasms 401Colorectal Neoplasms 373Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 233Stomach Neoplasms 227Uterine Cervical Neoplasms 225Testicular Neoplasms 216Non-Muscle Invasive Bladder Neoplasms 215Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 189Colonic Neoplasms 167Carcinoma, Hepatocellular 167Esophageal Neoplasms 165Endometrial Neoplasms 165Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 130Small Cell Lung Carcinoma 127Neuroblastoma 127

Interventions

proxalutamide 2Androgen Receptor Antagonists 2radium Ra 223 dichloride 1Pluvicto 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Metastatic Castrate Resistant Prostate Cancer (mCRPC) × Genitourinary × Clear all
NCT04597125 2026-05-11

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Bayer

Phase 4 Active not recruiting
654 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT06943495 2025-09-09

PRODIGY-2

CHU de Quebec-Universite Laval

Phase 1 Recruiting
60 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT03899467 2024-02-12

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Suzhou Kintor Pharmaceutical Inc,

Phase 2 Completed
61 enrolled 12 charts
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT02826772 2020-03-17

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Suzhou Kintor Pharmaceutical Inc,

Phase 1 Completed
40 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡